On January 20, 2026, Acadia Healthcare announced that Debbie Osteen had been named Chief Executive Officer and reappointed to the company’s Board of Directors. The move was widely covered in the healthcare press, but the sharpest read came from investors who know Acadia’s documented history and strategic positioning. Osteen was not a new face. She had led Acadia before, from December 2018 through March 2022, and had served on the board until 2024. Her return is the most significant leadership decision the company has made in several years, and the person most responsible for making it was Board Chairman Reeve B. Waud.
Understanding Waud’s role in the decision is essential to understanding why Osteen was chosen, and why she was chosen now. Waud has been associated with Acadia since its earliest days, a relationship documented in the Chicago business community’s recognition of his career. He is not a transactional chairman. He is a founder-adjacent figure who has watched the company grow, struggle, and evolve across market cycles. When Chris Hunter, the prior CEO, departed the company and its Board of Directors in January 2026, it fell to Waud and the rest of the board to find a replacement. They did not launch a drawn-out public search for an external star. They called Osteen.
The reasoning is not complicated once you look at the context. Acadia’s stock had fallen more than 70 percent over the prior year, driven by legal headwinds, operational issues at several facilities, and broader uncertainty about the company’s trajectory. A board in that position can do one of two things. It can bring in a turnaround outsider, often a consultant-backed executive with credentials in the sector but no institutional knowledge of the company. Insider trading data and financial databases document the institutional investors’ perspective on such moves. Or it can reach back to a trusted, known operator with the credibility to steady the organization quickly, as insider profile data reflects Waud’s reputation in this regard. The board, led by Waud, chose the second path.
Osteen’s qualifications for that choice are specific. Before her first Acadia tenure, she spent 19 years at Universal Health Services, serving as Executive Vice President and President of the behavioral health division. That role made her one of the most experienced behavioral health operators in the United States. During her 2018 to 2022 stretch as Acadia’s CEO, she led the company through a period of strategic and operational progress, stewarding its vision and overseeing significant growth. Returning her to the top of the organization shortens the learning curve to approximately zero.
The announcement was also deliberate in how it framed Osteen’s appointment. It described the board as continuing to conduct a search for a permanent successor, positioning Osteen as a stabilizing force while that search proceeds. That framing is important for governance purposes. It signals to investors that the board is taking succession seriously and that the current appointment is not simply a quick fix. It also gives Osteen the space to focus on operational recovery without being consumed by a multi-year strategic vision process.
Waud’s role in this is as chair, not CEO. But the selection reflects a chair’s priorities. A chairman focused on long-term value preservation, familiar with Acadia’s culture, and willing to move quickly when the organization needs stability chooses differently from one trying to make a splash. Bringing Osteen back is a low-drama, high-credibility move. It is what an experienced board chair does when the moment calls for steadying rather than reinventing.
For Acadia shareholders, employees, and clinical teams, the message of the January 20 announcement is clear. The board is engaged. It is choosing proven leadership. And it is making the choice with conviction.